Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende Patientenratgeber
Erweiterte Suche
Anmelden
nach oben
Endocrine Pathology
Erschienen in:

05.07.2016

Detection of Molecular Alterations in Medullary Thyroid Carcinoma Using Next-Generation Sequencing: an Institutional Experience

verfasst von: Shuanzeng Wei, Virginia A. LiVolsi, Kathleen T. Montone, Jennifer J. D. Morrissette, Zubair W. Baloch

Erschienen in: Endocrine Pathology | Ausgabe 4/2016

Einloggen, um Zugang zu erhalten

Abstract

Medullary thyroid carcinoma (MTC) harbors rearranged during transfection (RET) gene and rarely RAS gene mutations. The knowledge of the type of gene mutation in MTC is important to determine the treatment of the patients and the management of their family members. Targeted next-generation sequencing with a panel of 47 genes was performed in a total of 12 cases of sporadic (9/12) and hereditary MTC (3/12). Two of three hereditary MTCs had RET/C634R mutation, while the other one harbored two RET mutations (L790F and S649L). All the sporadic MTC had RET/M918T mutation except one case with HRAS mutation. Next-generation sequencing (NGS) can provide comprehensive analysis of molecular alterations in MTC in a routine clinical setting, which facilitate the management of the patient and the family members.
Literatur
1.
Moura MM, Cavaco BM, Pinto AE, Leite V: High prevalence of RAS mutations in RET-negative sporadic medullary thyroid carcinomas. J Clin Endocrinol Metab 2011, 96(5):E863–E868.CrossRefPubMed
2.
Ciampi R, Mian C, Fugazzola L, Cosci B, Romei C, Barollo S, Cirello V, Bottici V, Marconcini G, Rosa PM et al: Evidence of a low prevalence of RAS mutations in a large medullary thyroid cancer series. Thyroid 2013, 23(1):50–57.CrossRefPubMed
3.
Figlioli G, Landi S, Romei C, Elisei R, Gemignani F: Medullary thyroid carcinoma (MTC) and RET proto-oncogene: mutation spectrum in the familial cases and a meta-analysis of studies on the sporadic form. Mutat Res 2013, 752(1):36–44.CrossRefPubMed
4.
DeLellis RA: Pathology and genetics of tumours of endocrine organs, vol. 8: IARC; 2004.
5.
6.
Hundahl SA, Fleming ID, Fremgen AM, Menck HR: A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the US, 1985-1995. Cancer 1998, 83(12):2638–2648.CrossRefPubMed
7.
Kebebew E, Ituarte PH, Siperstein AE, Duh QY, Clark OH: Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer 2000, 88(5):1139–1148.CrossRefPubMed
8.
Margraf RL, Crockett DK, Krautscheid PM, Seamons R, Calderon FR, Wittwer CT, Mao R: Multiple endocrine neoplasia type 2 RET protooncogene database: repository of MEN2-associated RET sequence variation and reference for genotype/phenotype correlations. Hum Mutat 2009, 30(4):548–556.CrossRefPubMed
9.
Bihan H, Murat A, Fysekidis M, Al-Salameh A, Schwartz C, Baudin E, Thieblot P, Borson-Chazot F, Guillausseau PJ, Cardot-Bauters C et al: The clinical spectrum of RET proto-oncogene mutations in codon 790. Eur J Endocrinol 2013, 169(3):271–276.CrossRefPubMed
10.
Kloos RT, Eng C, Evans DB, Francis GL, Gagel RF, Gharib H, Moley JF, Pacini F, Ringel MD, Schlumberger M: Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 2009, 19(6):565–612.CrossRefPubMed
11.
Dvorakova S, Vaclavikova E, Sykorova V, Vcelak J, Novak Z, Duskova J, Ryska A, Laco J, Cap J, Kodetova D et al: Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinomas. Mol Cell Endocrinol 2008, 284(1–2):21–27.CrossRefPubMed
12.
Boichard A, Croux L, Al Ghuzlan A, Broutin S, Dupuy C, Leboulleux S, Schlumberger M, Bidart JM, Lacroix L: Somatic RAS mutations occur in a large proportion of sporadic RET-negative medullary thyroid carcinomas and extend to a previously unidentified exon. J Clin Endocrinol Metab 2012, 97(10):E2031–E2035.CrossRefPubMedPubMedCentral
13.
Wells SA, Jr., Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M, Baudin E, Elisei R, Jarzab B, Vasselli JR et al: Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol 2012, 30(2):134–141.CrossRefPubMed
14.
Zupan A, Glavač D: The development of rapid and accurate screening test for RET hotspot somatic and germline mutations in MEN2 syndromes. Exp Mol Pathol 2015, 99(3):416–425.CrossRefPubMed
15.
Aziz N, Zhao Q, Bry L, Driscoll DK, Funke B, Gibson JS, Grody WW, Hegde MR, Hoeltge GA, Leonard DG et al: College of American Pathologists’ laboratory standards for next-generation sequencing clinical tests. Arch Pathol Lab Med 2015, 139(4):481–493.CrossRefPubMed
16.
17.
Sehgal AR, Gimotty PA, Zhao J, Hsu J-M, Daber R, Morrissette JD, Luger SM, Loren AW, Carroll M: DNMT3A mutational status affects the results of dose-escalated induction therapy in acute myelogenous leukemia. Clin Cancer Res 2015:clincanres. 0327.2014.
18.
Gleeson FC, Kipp BR, Voss JS, Campion MB, Minot DM, Tu ZJ, Klee EW, Sciallis AP, Graham RP, Lazaridis KN: Endoscopic Ultrasound Fine-Needle Aspiration Cytology Mutation Profiling Using Targeted Next-Generation Sequencing Personalized Care for Rectal Cancer. Am J Clin Pathol 2015, 143(6):879–888.CrossRefPubMed
19.
Valero III V, Saunders TJ, He J, Weiss MJ, Cameron JL, Dholakia A, Wild AT, Shin EJ, Khashab MA, O’Broin-Lennon AM: Reliable Detection of Somatic Mutations in Fine Needle Aspirates of Pancreatic Cancer With Next-generation Sequencing. Ann Surg 2015, May 27, 2015.
20.
Chen H, Sippel RS, O’Dorisio MS, Vinik AI, Lloyd RV, Pacak K: The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer. Pancreas 2010, 39(6):775–783.CrossRefPubMedPubMedCentral
21.
Karnes HE, Duncavage EJ, Bernadt CT: Targeted next-generation sequencing using fine-needle aspirates from adenocarcinomas of the lung. Cancer Cytopathol 2014, 122(2):104–113.CrossRefPubMed
22.
Kanagal-Shamanna R, Portier BP, Singh RR, Routbort MJ, Aldape KD, Handal BA, Rahimi H, Reddy NG, Barkoh BA, Mishra BM et al: Next-generation sequencing-based multi-gene mutation profiling of solid tumors using fine needle aspiration samples: promises and challenges for routine clinical diagnostics. Mod Pathol 2014, 27(2):314–327.CrossRefPubMed
23.
Wei S, Lieberman D, Morrissette JJ, Baloch ZW, Roth DB, McGrath C: Using "residual" FNA rinse and body fluid specimens for next-generation sequencing: An institutional experience. Cancer Cytopathol 2015.
24.
Warth A, Penzel R, Brandt R, Sers C, Fischer JR, Thomas M, Herth FJ, Dietel M, Schirmacher P, Blaker H: Optimized algorithm for Sanger sequencing-based EGFR mutation analyses in NSCLC biopsies. Virchows Arch 2012, 460(4):407–414.CrossRefPubMed
25.
Krampitz GW, Norton JA: RET gene mutations (genotype and phenotype) of multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma. Cancer 2014, 120(13):1920–1931.CrossRefPubMed
26.
Mulligan LM: RET revisited: expanding the oncogenic portfolio. Nat Rev Cancer 2014, 14(3):173–186.CrossRefPubMed
27.
Frank-Raue K, Machens A, Scheuba C, Niederle B, Dralle H, Raue F: Difference in development of medullary thyroid carcinoma among carriers of RET mutations in codons 790 and 791. Clin Endocrinol (Oxf) 2008, 69(2):259–263.CrossRef
28.
Wells SA, Jr., Pacini F, Robinson BG, Santoro M: Multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma: an update. J Clin Endocrinol Metab 2013, 98(8):3149–3164.CrossRefPubMed
29.
Colombo-Benkmann M, Li Z, Riemann B, Hengst K, Herbst H, Keuser R, Gross U, Rondot S, Raue F, Senninger N et al: Characterization of the RET protooncogene transmembrane domain mutation S649L associated with nonaggressive medullary thyroid carcinoma. Eur J Endocrinol 2008, 158(6):811–816.CrossRefPubMed
30.
Chernock RD, Hagemann IS: Molecular pathology of hereditary and sporadic medullary thyroid carcinomas. Am J Clin Pathol 2015, 143(6):768–777.CrossRefPubMed
31.
Moura MM, Cavaco BM, Leite V: RAS proto-oncogene in medullary thyroid carcinoma. Endocr Relat Cancer 2015, 22(5):R235–R252.CrossRefPubMed
Metadaten
Titel
Detection of Molecular Alterations in Medullary Thyroid Carcinoma Using Next-Generation Sequencing: an Institutional Experience
verfasst von
Shuanzeng Wei
Virginia A. LiVolsi
Kathleen T. Montone
Jennifer J. D. Morrissette
Zubair W. Baloch
Publikationsdatum
05.07.2016
Verlag
Springer US
Erschienen in
Endocrine Pathology / Ausgabe 4/2016
Print ISSN: 1046-3976
Elektronische ISSN: 1559-0097
DOI
https://doi.org/10.1007/s12022-016-9446-3

Weitere Artikel der Ausgabe 4/2016

Stage-Specific Embryonic Antigen-1 (SSEA-1) Expression in Thyroid Tissues

Medullary Thyroid Carcinoma: Recent Advances Including MicroRNA Expression

Hürthle Cells Adenoma of the Thyroid with Post-surgical Implants in the Neck: Clinical, Morphological, and Molecular Analysis of Three Cases

Detailed Lymph Node Sectioning of Papillary Thyroid Carcinoma Specimen Increases the Number of pN1a Patients

Bronchial Paraganglioma with SDHB Deficiency

Should Core Needle Biopsy be Used in the Evaluation of Thyroid Nodules?

Neu im Fachgebiet Pathologie

DNA mixture deconvolution using fully continuous models EuroForMix and EFMrep

  • Open Access
  • Originalien

Mixture deconvolution is a powerful tool for inferring individual DNA profiles from DNA mixtures for subsequent transmission to a database or database queries. To carry out deconvolution, a mixed trace can be interpreted either manually by an …

Energie und Verletzungspotenzial von gezielt aus einem Fahrzeug abgeworfenen Steinen nach Durchschlag durch eine Pkw-Windschutzscheibe

Wir berichten aus Anlass eines Strafverfahrens über Versuche und deren biomechanische Bewertung hinsichtlich des möglichen Verletzungspotenzials von Steinen, welche vorsätzlich im Begegnungsverkehr auf entgegenkommende Fahrzeuge geworfen werden …

Durchführungsrealität der Komplexmethode zur Todeszeiteingrenzung an deutschen rechtsmedizinischen Instituten

Die Komplexmethode nach Henssge und Madea gilt als der Goldstandard für die Eingrenzung des Todeszeitintervalls im frühen postmortalen Intervall [ 1 , 2 ]. Der temperaturbasierte Methodenanteil gilt als gut etabliert [ 1 ]. Dies gilt nur mit …

Stellungnahme der Spurenkommission zu Ringversuchen zum Zweck der Qualitätssicherung in forensisch-molekulargenetischen Laboratorien

Die Spurenkommission wurde in den 1980er-Jahren gegründet und bildet eine Arbeitsgruppe innerhalb der Deutschen Gesellschaft für Rechtsmedizin (DGRM). Zu den Kernaufgaben der Spurenkommission gehören das Verfassen von Empfehlungen für die …